MrF. We all acknowledge you completed a year 9 science project which accordingly affords you the ability to speak with authority on all manner of science topics.
In lieu of the above, perhaps you could explain to this thread exactly why you believe the Monash Trauma Group and the IHL medical board have blundered in their approach to this clinical trial?
Dr Stuart McDonald is a research Fellow with the Department of Neuroscience having completed a PhD in 2012. He specializes in the injured brain with 53 publications and 561 citations.
He is assisted by Associate Professor Richelle Mychasiuk who has a Masters in Forensic Molecular Biology, a BSc in Psychology and a PhD in Neuroscience. There’s also Associate Professor Sandy Schultz who is an expert in underlying pathophysiological mechanisms, bio markers and the treatment of traumatic brain injury.
Now I’m not sure what you’re planning to contribute towards this clinical study but I’m increasingly confident that you don’t have the intellectual horse power to add more value than a $3 coin.
We all appreciate your interest in waxing lyrical about the science of medicine and it’s corresponding economic value but I’d actually prefer you just pissed off and let the real experts take care of IHL and it’s shareholders. Get my drift coach?
IHL Price at posting:
20.5¢ Sentiment: Buy Disclosure: Held
